Overall market sentiment has been high on Revance Therapeutics Inc (RVNC) stock lately. RVNC receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Revance Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RVNC!
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With RVNC Stock Today?
Revance Therapeutics Inc (RVNC) stock is trading at $13.24 as of 3:31 PM on Friday, Feb 25, a gain of $0.31, or 2.4% from the previous closing price of $12.93. The stock has traded between $12.50 and $13.45 so far today. Volume today is less active than usual. So far 323,345 shares have traded compared to average volume of 652,842 shares.
To see InvestorsObserver's Sentiment Score for Revance Therapeutics Inc click here.
More About Revance Therapeutics Inc
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in research and development of aesthetic and therapeutic products.
Click Here to get the full Stock Report for Revance Therapeutics Inc stock.